Found 368 clinical trials
HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma
. Researchers want to see if this therapy fights kidney cancer cells. Metastatic renal cell carcinoma (RCC) is an incurable condition. Current therapy for this disease consists of the serial administration
- 144 views
- 22 Dec, 2020
- 1 location
PHASE III RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL EVALUATING THE USE OF ADJUVANT ENDOCRINE THERAPY +/- ONE YEAR OF EVEROLIMUS IN PATIENTS WITH HIGH-RISK, HORMONE RECEPTOR-POSITIVE AND HER2/NEU NEGATIVE BREAST CANCER.
PHASE III RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL EVALUATING THE USE OF ADJUVANT ENDOCRINE THERAPY +/- ONE YEAR OF EVEROLIMUS IN PATIENTS WITH HIGH-RISK, HORMONE RECEPTOR-POSITIVE AND HER2/NEU NEGATIVE BREAST CANCER.
- 220 views
- 24 Nov, 2020
- 1 location
AREN03B2: Renal Tumors Classification, Biology, and Banking Study
AREN03B2: Renal Tumors Classification, Biology, and Banking Study
- 106 views
- 08 Nov, 2020
- 1 location
AREN03B2: Study of Kidney Tumors in Young Patients
AREN03B2: Study of Kidney Tumors in Young Patients
- 36 views
- 08 Nov, 2020
- 1 location
A Phase 1b, Dose-escalation Study of Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) in Combination With REGN2810 (Anti-PD-1) in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC)
This is a Phase 1b, open-label, multi-center, dose-escalation trial of Pexa-Vec plus REGN2810 in patients with metastatic or unresectable renal cell carcinoma (RCC). The trial consists of a dose-escalation stage, where the maximum feasible dose of Pexa-Vec in combination with REGN2810 will be determined, followed by an expansion stage. During …
- 0 views
- 23 Nov, 2020
- 3 locations
A Phase 1/1b Study of Sitravatinib in Combination with Nivolumab and Ipilimumab in Patients with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies
Study 516-008 is an open-label Phase 1 dose escalation/Phase 1b dose expansion study evaluating the safety and tolerability, clinical activity, and PK of sitravatinib in combination with nivolumab and ipilimumab for the treatment of ccRCC and potentially other solid tumor types. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor …
- 27 views
- 15 Sep, 2020
- 1 location
Procurement of Human Biospecimens for Research
Procurement of Human Biospecimens for Research
- 80 views
- 23 Nov, 2020
- 1 location
Procurement of Human Biospecimens for Research
Procurement of Human Biospecimens for Research
- 52 views
- 23 Nov, 2020
- 1 location
Chemotherapy Before and After Surgery in Treating Children With Wilm's Tumor
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving combination chemotherapy before surgery may shrink the tumor so it can be removed during surgery. Giving more chemotherapy after surgery may kill any remaining tumor cells. It is not …
- 9 views
- 07 Nov, 2020
- 1 location
MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia
To compare the efficacy of Medroxyprogesterone Acetate with dydrogesterone in patients having endometrial hyperplasia (EH) without atypia.
- 0 views
- 25 Jan, 2021
- 1 location